Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase

Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma

EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs

Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM

Latest in combination therapy for NDMM patients

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma

Initial treatment options for relapsed/refractory multiple myeloma patients